2004
Electrocardiographic safety profile and monitoring guidelines in pediatric psychopharmacology
Blair J, Taggart B, Martin A. Electrocardiographic safety profile and monitoring guidelines in pediatric psychopharmacology. Journal Of Neural Transmission 2004, 111: 791-815. PMID: 15205999, DOI: 10.1007/s00702-004-0153-8.Peer-Reviewed Original ResearchConceptsPediatric psychopharmacologyQTc prolongationQTc intervalNumber of medicationsTricyclic antidepressant desipramineAdult patientsYounger patientsElectrocardiographic monitoringAlpha agonistsSafety profileDeadly arrhythmiasAntidepressant desipramineSudden deathAdverse effectsMost reportsPatientsPsychopharmacologyProlongationCurrent knowledgeChildrenReportGuidelinesAntipsychoticsMedicationsTorsades
2003
Trends in Psychotropic Medication Costs for Children and Adolescents, 1997-2000
Martin A, Leslie D. Trends in Psychotropic Medication Costs for Children and Adolescents, 1997-2000. JAMA Pediatrics 2003, 157: 997-1004. PMID: 14557161, DOI: 10.1001/archpedi.157.10.997.Peer-Reviewed Original ResearchConceptsCostly medicationsSelective serotonin reuptake inhibitorsPsychotropic medication costsPsychotropic medication utilizationSerotonin reuptake inhibitorsWarrants further studyMental health outpatientsMedication utilizationAtypical antidepressantsAtypical antipsychoticsPharmacy claimsReuptake inhibitorsMedication costsPsychotropic drugsDrug categoriesMedicationsNational databaseDrugsOverall useFurther studiesChildrenPrescription pricesAntipsychoticsAntidepressantsOutpatients
2002
Effects of Development on Olanzapine-Associated Adverse Events
WOODS SW, MARTIN A, SPECTOR SG, MCGLASHAN TH. Effects of Development on Olanzapine-Associated Adverse Events. Journal Of The American Academy Of Child & Adolescent Psychiatry 2002, 41: 1439-1446. PMID: 12447030, DOI: 10.1097/00004583-200212000-00015.Peer-Reviewed Original ResearchConceptsLiver function abnormalitiesAdverse eventsFunction abnormalitiesAtypical antipsychoticsComplaint riskWeight gainAtypical antipsychotic medicationsExtrapyramidal syndromeTardive dyskinesiaProlactin increaseAntipsychotic medicationAdolescent patientsRisk ratioPatient exposureSurveillance databaseAge groupsOlanzapineComplaintsConfidence intervalsExposure estimatesAntipsychoticsSedationPatientsChildrenAdults